secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0000950170-23-009485
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma reports FY2022 net loss $34.7M; neffy NDA under FDA review, PDUFA mid-2023
--------------------------------------------------------------------------------

- Net loss of $14.4M for Q4 2022 and $34.7M for full year 2022; cash & investments $274.4M as of Dec 31, 2022.
- NDA for neffy (intranasal epinephrine) accepted by FDA; PDUFA target action date anticipated in mid-2023.
- MAA for neffy also under review by EMA; company reacquired European rights.
- R&D expenses $4.7M (Q4) and $18.4M (FY); G&A $10.7M (Q4) and $18.5M (FY).
- Cash runway sufficient for at least three years; preparing for potential U.S. launch in 2023 if approved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/0000950170-23-009485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017023009485/sbtx-20230323.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-009485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer